Your browser doesn't support javascript.
loading
Two Novel and Three Recurrent Mutations in the Mevalonate Pathway Genes in Chinese Patients with Porokeratosis.
Wang, Xiuping; Ouyang, Xiaoliang; Zhang, Deng; Zhu, Yunxia; Wu, Liang; Xiao, Zhen; Yu, Simin; Li, Wei; Li, Chunming.
Affiliation
  • Wang X; Department of Dermatology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic of China.
  • Ouyang X; Department of Plastic Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic of China.
  • Zhang D; Department of Dermatology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic of China.
  • Zhu Y; Department of Dermatology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic of China.
  • Wu L; Department of Dermatology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic of China.
  • Xiao Z; Department of Dermatology, Taiyuan Central Hospital, Taiyuan, Shanxi, People's Republic of China.
  • Yu S; Department of Dermatology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic of China.
  • Li W; Department of Plastic Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic of China.
  • Li C; Department of Dermatology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic of China.
Clin Cosmet Investig Dermatol ; 17: 191-197, 2024.
Article in En | MEDLINE | ID: mdl-38283795
ABSTRACT

Purpose:

Porokeratosis (PK) is a chronic autosomal-dominant cutaneous keratinization disorder exhibiting clinical and genetic heterogeneity. Mevalonate decarboxylase (MVD), farnesyl diphosphate synthase (FDPS), phosphomevalonate kinase(PMVK), and mevalonate kinase genes(MVK), which encode the mevalonate pathway, are disease-causing genes in PK. Patients and

Methods:

Data and blood samples were collected from two Chinese families and five sporadic patients with porokeratosis. Whole-exome and Sanger sequencing were performed to detect pathogenic gene mutation in the patients.

Results:

Five heterozygous mutations were identified, including a novel FDPS stop-gain mutation c.438T>G (p.Tyr146Ter), a novel MVD missense mutation c.683G>C (p.R228P), and three previously reported MVD mutations c.746T>C (p.F249S), c.875A>G (p.N292S), and c.1111_1113del (p.371_371del). The novel FDPS c.438T>G mutation was predicted as "disease-causing" (p = 1) by Mutation Taster. The other novel MVD c.683G>C was also predicted as "deleterious" (score = 0.00) by Sorting Intolerant From Tolerant (SIFT), "probably damaging" (score = 1) by PolyPhen2, and "disease-causing" (p = 0.999) by Mutation Taster.

Conclusion:

Our results extended the mutation spectrum of mevalonate pathway genes in porokeratosis and provided useful strategies for a more accurate diagnosis and genetic counseling.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Clin Cosmet Investig Dermatol Year: 2024 Document type: Article Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Clin Cosmet Investig Dermatol Year: 2024 Document type: Article Country of publication: